Wilson Sonsini and Latham & Watkins advised Prometheus Biosciences on the deal, while Davis Polk & Wardwell advised the representatives of the several underwriters. Prometheus Biosciences,...
Prometheus Biosciences’ $500 Million Shares Offering
Ligand’s Spin-off of OmniAb Business
Latham & Watkins represented Ligand in the transaction, while Weil, Gotshal & Manges represented APAC. Ligand Pharmaceuticals Incorporated has announced the signing of a definitive merger...
Janux Therapeutics’ $193.8 Million IPO
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics, Inc. on the deal, while Latham & Watkins LLP represented the underwriters. Janux Therapeutics, Inc., a biopharmaceutical company...
Connect Biopharma’s $219.9 Million Initial Public Offering
Latham & Watkins LLP and Maples and Calder represented Connect Biopharma in the transaction. Global Law Office and Davis Polk advised joint book-running managers. Connect Biopharma...